STTR Phase I: Development of an Intranasal Vaccine for COVID-19 — NSF Award to DYNAMIC ENTROPY TECHNOLOGY, LLC (WA, $276,000)
The broader impact /commercial potential of this Small Business Technology Transfer (STTR) Phase I project is development of a novel, safe and effective, non-invasive, vaccine for the COVID-19 pandemic. Currently there is no approved vaccine for SARS-CoV-2, and some candidates are administered intramuscularly. The prop
| Award title | STTR Phase I: Development of an Intranasal Vaccine for COVID-19 |
|---|---|
| Award ID | 2032325 |
| Awardee | DYNAMIC ENTROPY TECHNOLOGY, LLC |
| City | RICHLAND |
| State | WA |
| Amount obligated | $276,000 |
| Principal investigator | Maoqi Feng |
| Program | STTR Phase I, SBIR Outreach & Tech. Assist |
| Start date | 10/01/2020 |
| Abstract | The broader impact /commercial potential of this Small Business Technology Transfer (STTR) Phase I project is development of a novel, safe and effective, non-invasive, vaccine for the COVID-19 pandemic. Currently there is no approved vaccine for SARS-CoV-2, and some candidates are administered intramuscularly. The proposed intranasal vaccine directly interacts with the respiratory tract and may provide improved protection and virus clearance. The proposed vaccine is non-invasive, easy to adminis |
| Source | NSF Awards |
$799/mo
Try NSFGrants →